Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade
Open Access
- 10 October 2025
- journal article
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (1) , 100173
Abstract
No abstract availableFunding Information
- Leukemia and Lymphoma Society
- Bristol Myers Squibb
- Lymphoma Research Foundation
- American Society of Hematology
This publication has 13 references indexed in Scilit:
- Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialNature Medicine, 2025
- Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphomaBlood, 2025
- Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 StudyBlood, 2023
- Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerScience Immunology, 2023
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin LymphomaClinical Lymphoma Myeloma and Leukemia, 2021
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialThe Lancet Haematology, 2020
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytesJournal of Clinical Investigation, 2017
- Ipilimumab for Patients with Relapse after Allogeneic TransplantationNew England Journal of Medicine, 2016
- Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin LymphomaClinical Cancer Research, 2009
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationBlood, 2009